Topical Therapies for Glaucoma and Ocular Hypertension: An Update on Current Practice

Abstract

Get full access to this article

View all access options for this article.

References

Alward

W.L.M.

. Medical management of glaucoma. N Engl J Med 1998; 339: 1298–307.

Kass

M.A.

Heuer

D.K.

Higginbotham

E.J.

The Ocular Hypertension Treatment Study. A randomised trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Arch Ophthalmol 2002; 120: 701–13.

The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429–40.

Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487–97.

Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498–505.

Mao

L.K.

Stewart

W.C.

Shields

M.B.

. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111: 51–5.

Bateman

D.N.

Clark

Azuara-Blanco

Bain

Forrest

. The impact of new drugs on management of glaucoma in Scotland: observational study. BMJ 2001; 323: 1401–2.

Bateman

D.N.

Clark

Azuara-Blanco

Bain

Forrest

. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol 2002; 86: 551–4.

Paikal

Coleman

A.L.

. Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998. Ophthalmology 2002; 109: 1372–6.

10.

Rouland J-F, Le Pen C, and the Ophthalmologists of the GLAUCOMA Study. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol 2003; 13(Suppl 4): S5–20.

11.

Diestelhorst

Schaefer

C.P.

Beusterien

K.M.

Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study.

Eur J Ophthalmol 2003; 13(Suppl 4): S21–9.

12.

Bernard

L.M.

Althin

Dhawan

Grima

D.T.

Lam

Aballéa

. Clinical and economic impacts of latanoprost 0.005% in the first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 2003; 13(Suppl 4): S30–43.

13.

Reardon

Schwartz

G.F.

Mozaffari

. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003; 13(Suppl 4): S44–52.

14.

Baudouin

Rouland

J-F

Le Pen

. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France. Eur J Ophthalmol 2003; 13(Suppl 4): S53–60.